The NHS is like a large sow with many teats, from which provider piglets draw succour. One of the most robust piglets in the sty is the pharmaceutical industry.
Take, for instance, the current debate about 'co-payments' for cancer patients. With NICE declining some products of marginal cost-effectiveness, industry is encouraging its compatriots in the medical profession and elsewhere to demand that where patients buy treatments declined by NICE, the administration of the drugs should be provided by the NHS.